- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Lifesci
Review, Journal: DNA Vaccines: Their Formulations, Engineering and Delivery. (Pubmed Central) - Jan 22, 2024
Along with the successful COVID mRNA vaccines, the first DNA vaccine for human use, the Indian ZyCovD vaccine against SARS-CoV-2, was approved in 2021...We then cover some of the emerging science in the field of DNA vaccines, notably efforts to optimize delivery systems, better engineer delivery apparatuses, identify optimal delivery sites, personalize cancer immunotherapy through DNA vaccination, enhance adjuvant science through gene adjuvants, enhance off-target and heritable immunity through epigenetic modification, and predict epitopes with bioinformatic approaches. We also discuss the major limitations of DNA vaccines and we aim to address many theoretical concerns.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Lifesci, Spikevax (elasomeran) / Moderna
Journal: Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters. (Pubmed Central) - Jan 8, 2024
To date, only one DNA vaccine (ZyCoV-D) has been authorized for emergency use in India...Here, we report that plasmid encoding a trimeric spike protein with LNP delivery (pTS/LNP), similar to those in Moderna's COVID-19 vaccine, induced more effective humoral responses than naked pTS or pTS delivered via electroporation...Importantly, pTS/LNP immunization exhibits enhanced cross-neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and protects hamsters from the challenge of SARS-CoV-2 (Wuhan strain and the Omicron BA.1 variant). This study indicates that pDNA/LNPs as a promising platform could be a next-generation vaccine technology.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Lifesci
Journal: Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector. (Pubmed Central) - Dec 25, 2023
P2
For example, vaccination of patients with the ZyCoV-D DNA vaccine using the Tropis device is effective against COVID19, well tolerated, and licensed. Here we show that split-dose, multi-site administration and intradermal delivery via the Tropis biojector increase the delivery of pBI-11 DNA vaccine, enhance HPV antigen-specific CD8+ T-cell responses, and improve anti-tumor therapeutic effects, suggesting its translational potential to treat HPV16/18 infection and disease.
- |||||||||| Review, Journal: Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). (Pubmed Central) - Apr 4, 2023
Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Covid-19 vaccines and variants of concern: A review. (Pubmed Central) - Jul 10, 2022
All nine had an efficacy over 50% against symptomatic Covid-19 disease: NVX-CoV2373 (∼96%), BNT162b2 (∼95%), mRNA-1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP-CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%)...Promising Covid-19 vaccines such as WIBP-CorV, AD5-nCOV, ZyCoV-D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS-CoV-2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid-19 vaccination and introduces some promising Covid-19 vaccine candidates.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Cadila, Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen
Review, Journal: "Vaccinate every child against COVID-19": A scientific or socioeconomic need? (Pubmed Central) - Jul 10, 2022
Vaccinating children is not easy as it has taken nearly 1 year to vaccinate half of the adult Indian population. In these circumstances, rather than "vaccine for all," "vaccine for (chronically) ill" is the only feasible solution for children.
- |||||||||| Retrospective data, Review, Journal: Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 - 21 years old: A Systematic Review and Meta-analysis. (Pubmed Central) - Jul 9, 2022
Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN)...Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Cadila
PharmaJet (Theater 1) - Jun 4, 2022 - Abstract #BIO2022BIO_418;
Our NFIS addresses vaccine hesitancy with a preferred patient and caregiver experience, and we have established a proven path to commercialization, most recently as the exclusive delivery technology for ZyCov-D, the world’s first, commercialized-for-human-use, plasmid DNA vaccine...Our hand-held needle-free medical devices are also safe, fast, and easy-to-use and address common injection concerns such as needle-stick injuries, needle reuse and needle-phobia. With registrations in over 25 countries, PharmaJet is prepared to contribute to equitable vaccine access.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Cadila
P3 data, P3 data: top line, Journal: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. (Pubmed Central) - Apr 5, 2022
With registrations in over 25 countries, PharmaJet is prepared to contribute to equitable vaccine access. In this interim analysis, ZyCoV-D vaccine was found to be efficacious, safe, and immunogenic in a phase 3 trial.
- |||||||||| ZyCov-D (Coronavirus DNA Vaccine) / Zydus Cadila
Preclinical, Journal: Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. (Pubmed Central) - Jul 11, 2021
Based on the animal studies proof-of-concept has been established and preclinical toxicology (PCT) studies were conducted in rat and rabbit model. Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also elicited Th-1 response as evidenced by elevated IFN-γ levels.
|
